Novo Nordisk had a record-breaking 2021 profit, but has reined in expectations for 2022
In 2021, Novo Nordisk has lifted both its revenue and profits to new heights, driven by great progress of its diabetes flagship semaglutide in both tablet and injection form. There are challenges ahead, however, the company warns, as it predicts less progress in 2022.
By Mikkel Aabenhus Hemmingsen, translated by Daniel Pedersen
2021 was a historically good year for Novo Nordisk, which has never achieved such high revenue and profit results before, the company’s full-year report, released on Wednesday morning, states.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
All eyes on Novo's new outlook on eve of 2021 report
For subscribers
Production issues could put a damper on Novo Nordisk's 2022
For subscribers
